ZAGREB, June 19 (Hina) - An expert commission of the Croatian Health Insurance Fund (HZZO) stated on Monday afternoon that it would analyse each individual case and its admissibility for the application of Dinutuximab Beta, a drug for children with the rare high-risk neuroblastoma.
Task force to analyse applicability of Dinutuximab Beta in each case
Only logged-in users can see full content details